New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Subscribe To Our Newsletter & Stay Updated
